Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s traded shares stood at 0.87 million during the latest session, with the company’s beta value hitting 0.87. At the last check today, the stock’s price was $7.53, to imply an increase of 0.87% or $0.06 in intraday trading. The RXRX share’s 52-week high remains $16.75, putting it -122.44% down since that peak but still an impressive 39.71% since price per share fell to its 52-week low of $4.54. The company has a valuation of $1.63B, with an average of 6.39 million shares over the past 3 months.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
After registering a 0.87% upside in the latest session, Recursion Pharmaceuticals Inc (RXRX) has traded red over the past five days. The stock hit a weekly high of 8.93, jumping 0.87% in its intraday price action. The 5-day price performance for the stock is -15.53%, and -29.91% over 30 days. With these gigs, the year-to-date price performance is -23.58%.
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
Looking at statistics comparing Recursion Pharmaceuticals Inc share performance against respective industry, we note that the company has underperformed competitors. Recursion Pharmaceuticals Inc (RXRX) shares are 15.57% up over the last 6 months, with its year-to-date growth rate lower than industry average at -3.16% against 9.60%. Revenue is forecast to shrink -23.50% this quarter before falling -10.50% for the next one. The rating firms project that company’s revenue will grow 26.00% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is $12.65 million. Meanwhile, for the quarter ending Jun 2024, a total of 6 analyst(s) estimate revenue growth to $13.17 million.Earnings reports from the last fiscal year show that sales brought in $12.13 million and $11.02 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 4.30% before jumping 19.50% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -43.41% for the past 5-year period. While 2024 is set for a -9.14% return in earnings, projections for the next 5 years are at 12.00% annually.
RXRX Dividends
Recursion Pharmaceuticals Inc has its next earnings report out in May. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Recursion Pharmaceuticals Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
